LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

Search

Glaukos Corp

Fermé

SecteurSoins de santé

94.87 -2.54

Résumé

Variation du prix de l'action

24h

Actuel

Min

94.25

Max

97.44

Chiffres clés

By Trading Economics

Revenu

15M

-18M

Ventes

1.2M

107M

BPA

-0.22

Marge bénéficiaire

-17.012

Employés

995

EBITDA

1.6M

-21M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+29.46% upside

Dividendes

By Dow Jones

Prochains Résultats

30 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

53M

5.4B

Ouverture précédente

97.41

Clôture précédente

94.87

Sentiment de l'Actualité

By Acuity

59%

41%

335 / 382 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Glaukos Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

20 mai 2025, 20:54 UTC

Acquisitions, Fusions, Rachats

PNC to Buy Private-Equity Agent Aqueduct Capital

20 mai 2025, 20:50 UTC

Résultats

Palo Alto Networks Posts Higher 3Q Sales, Profit Slips

20 mai 2025, 23:48 UTC

Acquisitions, Fusions, Rachats

Kraft Heinz Evaluating Strategic Transactions, Berkshire Hathaway Steps Away From Board -- Update

20 mai 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

20 mai 2025, 23:39 UTC

Market Talk

Gold Steady, Supported by Lingering U.S. Fiscal-Deficit Concerns -- Market Talk

20 mai 2025, 23:08 UTC

Market Talk

James Hardie's Repair & Remodel Outlook Surprises RBC -- Market Talk

20 mai 2025, 22:46 UTC

Acquisitions, Fusions, Rachats

Gold Road: Takeover Remains Subject to Independent Expert Findings; Shareholder, Court Approval

20 mai 2025, 22:45 UTC

Acquisitions, Fusions, Rachats

Gold Road: Notified Australia Government Has No Objections to Takeover by Gold Fields

20 mai 2025, 22:44 UTC

Actualités

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- 2nd Update

20 mai 2025, 22:20 UTC

Actualités

In Latest EV Pullback, Ford to Share Battery Plant With Nissan -- WSJ

20 mai 2025, 22:00 UTC

Résultats

ZTO Express (Cayman) 1Q Adj EPS 37c >ZTO

20 mai 2025, 22:00 UTC

Résultats

ZTO Express (Cayman) 1Q EPS 34c >ZTO

20 mai 2025, 22:00 UTC

Résultats

ZTO Express (Cayman) 1Q Rev $1.5B >ZTO

20 mai 2025, 21:44 UTC

Résultats

James Hardie Industries 4Q Adj EPS 36c >JHX

20 mai 2025, 21:44 UTC

Résultats

James Hardie Industries: Sees FY26 North America Net Sales Growth Up Low Single Digits >JHX

20 mai 2025, 21:44 UTC

Résultats

James Hardie Industries 4Q EPS 10c >JHX

20 mai 2025, 21:44 UTC

Résultats

James Hardie Industries 4Q Sales $972M >JHX

20 mai 2025, 20:52 UTC

Actualités

Elon Musk to Cut Back Political Spending -- 3rd Update

20 mai 2025, 20:52 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 mai 2025, 20:52 UTC

Market Talk

Mexican Stocks Near Record High As Trade Concerns Ease -- Market Talk

20 mai 2025, 20:30 UTC

Acquisitions, Fusions, Rachats

PNC Financial: Aqueduct Acquisition Expected to Close in Mid-Summer, Terms Won't be Disclosed >PNC

20 mai 2025, 20:28 UTC

Acquisitions, Fusions, Rachats

PNC Bank Agrees To Acquire Aqueduct Capital Group To Complement Harris Williams Capabilities >PNC

20 mai 2025, 20:23 UTC

Acquisitions, Fusions, Rachats

Tesla CEO Musk Says He Plans to Be at White House for a Couple Days Every Few Weeks

20 mai 2025, 20:22 UTC

Résultats

XP 1Q Adj EPS BRL2.29 >XP

20 mai 2025, 20:22 UTC

Résultats

XP 1Q Rev BRL4.345B >XP

20 mai 2025, 20:21 UTC

Acquisitions, Fusions, Rachats

Tesla CEO Musk: 'We're in the Big Bang of Intelligence Explosion'

20 mai 2025, 20:20 UTC

Actualités

Fed's Bostic Signals Longer Delay in Cutting Interest Rates -- Barrons.com

20 mai 2025, 20:19 UTC

Acquisitions, Fusions, Rachats

Tesla CEO Musk Says He Doesn't Currently Have Plans to Merge Tesla, xAI

20 mai 2025, 20:11 UTC

Actualités

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- Update

20 mai 2025, 20:09 UTC

Résultats

Palo Alto Networks 3Q Remaining Performance Obligation $13.5 B >PANW

Comparaison

Variation de prix

Glaukos Corp prévision

Objectif de Prix

By TipRanks

29.46% hausse

Prévisions sur 12 Mois

Moyen 124.09 USD  29.46%

Haut 165 USD

Bas 86 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

10

Achat

1

Maintien

1

Vente

Score Technique

By Trading Central

87.61 / 93Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

335 / 382Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.